Abivax SA
PAR:ABVX

Watchlist Manager
Abivax SA Logo
Abivax SA
PAR:ABVX
Watchlist
Price: 94.1 EUR -9.69%
Market Cap: 7.3B EUR

Net Margin
Abivax SA

0%
Current
0%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-229m
/
Revenue
0

Net Margin Across Competitors

No Stocks Found

Abivax SA
Glance View

Market Cap
7.3B EUR
Industry
Biotechnology

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

ABVX Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-229m
/
Revenue
0
What is the Net Margin of Abivax SA?

Based on Abivax SA's most recent financial statements, the company has Net Margin of 0%.

Back to Top